MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Idiopathic Pulmonary Fibrosis in Japan

LA JOLLA, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the?NASDAQ Global Market?(NASDAQ:MNOV) and the JASDAQ Market of the?Tokyo Stock Exchange?(Code Number: 4875), today announced that it has received a Notice of Allowance from the?Japan Patent Office?for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001)?for the treatment of idiopathic pulmonary fibrosis (IPF).